Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of Vassopresin in Septic Shock Prospective Multicenter Observational Study With Medication
Sponsor: Jamil Cedeño Mora
Summary
The aim of this observational study is to examine real-world clinical practice regarding the use of vasopressin as a second-line vasopressor in adult patients admitted to Intensive Care Units (ICUs) with septic shock. The study focuses on critically ill adults (≥18 years) diagnosed with septic shock and treated with norepinephrine and vasopressin. The main research questions are: * Does early initiation of vasopressin-defined by the norepinephrine dose at the time of introduction-reduce mortality in patients with septic shock? * What is the impact of vasopressin as a second vasopressor on renal function and the progression of organ dysfunction in septic shock patients? Participants will: * Be admitted to an ICU with a diagnosis of septic shock. * Receive vasopressin as an adjunct to norepinephrine for hemodynamic support. * Be monitored daily throughout their ICU stay, with data collected through a dedicated REDCap system. * Have relevant clinical data pseudonymized and incorporated into the study database for statistical analysis.
Official title: Use of Vasopressin in Septic Shock.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1200
Start Date
2025-10-01
Completion Date
2028-01-01
Last Updated
2025-12-15
Healthy Volunteers
No
Conditions
Interventions
Usage of vasopressin (VAP) as a second-line vasopressor in septic shock patients.
A state-of-the-art line of research in septic shock management focuses on the potential use of a second vasopressor agent. Current efforts aim to determine which drug should be used and the optimal timing for its initiation. In line with this, the Surviving Sepsis Campaign 2021 clinical guide recommends considering vasopressin-arginine (VAP) as a second-line vasopressor when norepinephrine (NAD) doses exceed 0.25 µg/kg/min, although this suggestion is based on limited evidence and remains weak.
Locations (12)
Consorci Sanitari de Terrassa
Terrassa, BARCELONA, Spain
Hospital Universitario de Getafe
Getafe, Madrid, Spain
Hospital Universitario La Princesa
Madrid, Madrid, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Madrid, Spain
Hospital Universitario Clínico San Carlos
Madrid, Madrid, Spain
Hospital Universitario Doce de Octubre
Madrid, Madrid, Spain
Hospital Universitario La Paz
Madrid, Madrid, Spain
Hospital Universitario Puerta de Hierro
Majadahonda, Madrid, Spain
Hospital Universitario Rey Juan Carlos
Móstoles, Madrid, Spain
Hospital Universitario y Politécnico de La Fe
Valencia, Valencia, Spain
Hospital Universitario Miguel Servet
Zaragoza, ZARAGOZA, Spain